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Abstract
Simian varicella virus (SVV), the etiologic agent of naturally occurring varicella in primates, is genetically and antigenically
closely related to human varicella zoster virus (VZV). Early attempts to develop a model of VZV pathogenesis and latency in
nonhuman primates (NHP) resulted in persistent infection. More recent models successfully produced latency; however,
only a minority of monkeys became viremic and seroconverted. Thus, previous NHP models were not ideally suited to
analyze the immune response to SVV during acute infection and the transition to latency. Here, we show for the first time
that intrabronchial inoculation of rhesus macaques with SVV closely mimics naturally occurring varicella (chickenpox) in
humans. Infected monkeys developed varicella and viremia that resolved 21 days after infection. Months later, viral DNA was
detected only in ganglia and not in non-ganglionic tissues. Like VZV latency in human ganglia, transcripts corresponding to
SVV ORFs 21, 62, 63 and 66, but not ORF 40, were detected by RT-PCR. In addition, as described for VZV, SVV ORF 63 protein
was detected in the cytoplasm of neurons in latently infected monkey ganglia by immunohistochemistry. We also present
the first in depth analysis of the immune response to SVV. Infected animals produced a strong humoral and cell-mediated
immune response to SVV, as assessed by immunohistology, serology and flow cytometry. Intrabronchial inoculation of
rhesus macaques with SVV provides a novel model to analyze viral and immunological mechanisms of VZV latency and
reactivation.
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Introduction
Varicella zoster virus (VZV), a neurotropic alpha herpesvirus, is
the etiological agent of varicella (chickenpox). VZV establishes
latency in ganglia and can reactivate to produce herpes zoster
(shingles), a debilitating disease for the elderly and immunocom-
promised. Studies of VZV pathogenesis have been hampered by
the lack of an animal model that consistently recapitulates both the
virological and immunological hallmarks of both acute and latent
VZV infection. Experimental inoculation of mice, rats and
nonhuman primates (NHP) with VZV results in seroconversion
but not varicella [1,2,3]. In weanling guinea pigs, seroconversion,
viremia, an exanthem and animal-to-animal spread after VZV
infection have been found [4]. Although humoral and cellular
immune responses have been briefly characterized in the guinea
pig model, the scarcity of immunological tools specific for this
species have precluded in depth analysis [5,6]. Further, VZV does
not reactivate in any of these models. A SCID-humanized (SCID-
hu) mouse model was developed in which co-implants of human
fetal thymus/liver tissue were introduced under the kidney
capsule. Fetal skin was then introduced subcutaneously as full
thickness dermal grafts and later infected by injection of VZV-
infected cells into the implanted tissue [7]. Further studies showed
that the skin implants can also be infected and display hallmarks of
VZV lesions following intravenous transfer of VZV infected
tonsilar T cells [8]. Although this model contributed significantly
to our understanding of VZV dissemination and pathogenesis, the
chimeric and partially immunodeficient status of the host coupled
with the need for fetal liver, thymus, tonsils and skin, precluded in
depth studies of the role of the host immune response in the
establishment and maintenance of VZV latency.
Simian varicella virus (SVV) produces a naturally occurring
exanthematous disease in NHP that mimics human varicella [9].
Both virus genomes have been sequenced and are colinear, sharing
upto75%DNAsimilarity[10,11,12].Furthermore,SVVandVZV
encode antigenically related polypeptides [13,14,15]. Like VZV,
SVV becomes latent in ganglionic neurons [16,17,18,19] and
reactivates after environmental stress or immune suppression
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African green or Cynomolgus monkeys with SVV produces clinical
and pathological features in monkeys similar to those seen in
humans infected with VZV [9,23], the animals remain persistently
viremic for years [24,25]. Thus, it is not ideal to use these models to
characterize immunological control of VZV infection.
To address this limitation and study VZV latency, a model of
natural SVV infection was developed whereby African Green or
Cynomolgus monkeys were exposed to cage-mates that had been
experimentally inoculated with SVV [21,26]. While natural
infection resulted in rash and SVV DNA was detected only in
ganglia and not in liver or lung, features consistent with varicella
latency, seroconversion was random, and viremia was not found in
most animals. These observations, coupled with an unknown dose
and exact time of infection, make it difficult to study the kinetics of
the host immunological response to virus infection [21]. The goal
of this study was to investigate whether intrabronchial inoculation
of rhesus macaques with SVV would provide a more suitable
model of VZV pathogenesis and latency. In this manuscript, we
report that intrabronchial infection of rhesus macaques with SVV
reproduced all of the cardinal features of primary VZV infection
in humans.
Results
Intrabronchial inoculation of rhesus macaques with SVV
results in varicella, viremia and viral latency
Since VZV is transmitted through aerosolized droplets, we
inoculated four SVV-seronegative rhesus macaques (RM) once
intrabronchially with 4610
5 pfu SVV. All four animals developed
varicella either at 7- (24953 and 25043) or 10 (23942 and 23986)
days post infection (dpi, Figure 1A). The rash progressed until 14
dpi after which lesions began to heal and resolved by 21 dpi. The
severity of the rash varied between animals with 23986 displaying
the greatest number of lesions followed by 24953, 23942 and
25043. Skin punch biopsies of the lesions confirmed the presence
of both SVV DNA (Figure 1B) and SVV antigen (Figure 1C and
D). There was considerable variation in viral loads in the lesions
between animals and within the same animal (Figure 1B). This
variation could be due to differences in the stage of the lesion. Skin
biopsies obtained before infection were negative for both SVV
DNA (Figure 1B) as well as SVV antigen (data not shown).
SVV DNA loads in peripheral blood mononuclear cells
(PBMCs) (Figure 1E) and bronchial alveolar lavage (BAL) samples
(Figure 1F) were determined by quantitative real time PCR
(qPCR) using primers and probes specific for SVV ORF 21
(Table 1). SVV DNA was detected in PBMCs at 7 dpi, with a peak
at 10 dpi and undetectable by 21 dpi, whereas BAL samples
revealed SVV DNA first at 3 dpi, with a peak at 14 dpi and
returning to undetectable levels at 17–21 dpi. Viral DNA loads
were significantly higher (10
2–10
5 copies/100 ng) in BAL than in
PBMCs (2–8 copies/100 ng), likely reflecting the route of
infection. Monkeys were euthanized at 73 dpi (24953 and
25043) or 105 dpi (23942 and 23986) and all lymphoid tissues,
lung, liver, gastrointestinal tract, pancreas, salivary glands, kidney,
thyroid, dorsal root and trigeminal ganglia, brain and spinal cord
were examined for the presence of SVV DNA by qPCR. SVV
DNA was detected only in ganglia, but not in any other organ,
including lung or liver (Table 2 and data not shown), indicating
latent infection. Interestingly, the SVV viral loads in the ganglia
correlated with the rash severity during acute infection with 23986
displaying the most extensive rash and 25043 the least.
In latently infected human ganglia, transcripts specific for VZV
ORFs 21, 29, 62, 63 and 66 are present [27]. To determine if SVV
latency has a similar transcriptional pattern, SVV DNA-positive
ganglia were further analyzed for transcripts corresponding to
SVV ORFs 21, 29, 61 62, 63 and 66, as well as ORF 40, a major
capsid protein that is expected to be absent during latency (primer
and probes listed in Table 1). Transcripts specific for SVV ORFs
61, 21, 62, 63 and 66 were detected (Table 3). As expected SVV
ORF 40 specific transcripts were not detected SVV ORF 29-
specific transcripts were also not found (Table 3). VZV ORF 29 (a
single-stranded DNA-binding protein) -specific transcripts are
sometimes present and sometimes absent in latently infected
human ganglia. SVV ORF 61 specific transcripts were the most
abundant (Table 3). Both sense and antisense transcripts of SVV
ORF 61 were detected, and antisense transcripts were 5–9 times
more abundant than sense transcripts (Table 4), consistent with
findings of Ou et al. [28]. No transcripts were detected in control
PCR reactions in the absence of reverse transcriptase. We
routinely detect as little as one copy of the SVV ORFs listed
above in positive controls. Thus, as previously described for VZV,
SVV latency is associated with limited viral transcriptional
activity.
VZV ORF 63 protein is present in the cytoplasm of neurons in
latently infected human ganglia [29,30]. To determine whether
SVV ORF 63 protein is comparably localized, sections of
formalin-fixed ganglia from the side of the neuraxis opposite
to the one used for nucleic acid analysis were studied using
immunohistochemistry for SVV ORF 63 protein as well as for
SVV ORF 61 protein in light of the considerable abundance of
SVV ORF 61 transcripts. VZV ORF 63- or 61-specific rabbit
polyclonal antisera, which reacted with SVV-infected cells in
culture (Figure S1A, C) but not with uninfected Vero cells (Figure
S1B, D), were used in these studies. We detected SVV ORF 63
protein exclusively in the cytoplasm of ganglionic neurons in all
animals (Figure 2A and B). SVV ORF 61 protein was detected
in one ganglion from two monkeys (Table 5) in both the nucleus
and cytoplasm (Figure 2). Analysis of adjacent sections of
trigeminal ganglia from monkey 23942 revealed the presence
ofSVV ORF 63 but not61(Figure 2). Table 5 summarizes results
from ganglia of all 4 monkeys and shows that like VZV ORF63,
SVV ORF63 is consistently detected in the cytoplasm of neurons
in latently infected ganglia. Overall, these data suggest that SVV
i n f e c t i o ni nr h e s u sm a c a q u e sr e c a p i t u l a t e sk e yf e a t u r e so fV Z V
latency.
Author Summary
Varicella zoster virus (VZV) is a ubiquitous herpesvirus that
causes chickenpox (varicella) and establishes a life-long
latent infection in humans. VZV can then reactivate
causing herpes zoster, commonly known as shingles, a
painful and debilitating disease that can be life-threaten-
ing in elderly and immunocompromised individuals. Our
understanding of immunological factors that control VZV
replication is limited due to the fact that VZV causes
disease only in humans. Simian varicella virus (SVV) is a
simian counterpart of VZV that infects nonhuman prima-
tes. Our study showed for the first time that infection of
rhesus macaques with SVV recapitulates key aspects of
VZV infection from chickenpox and the resolution of acute
viremia to the establishment of latency in ganglia, and the
development of B and T cell responses to virus. This model
will allow us to improve our understanding of the immune
response to varicella virus, and to develop and test
vaccines and antiviral drugs that can reduce the incidence
of shingles and its attendant neurological complications.
Primate Model for Varicella Zoster Virus Infection
PLoS Pathogens | www.plospathogens.org 2 November 2009 | Volume 5 | Issue 11 | e1000657Figure 1. Varicella and the presence of SVV DNA and viral antigen in rhesus macaques inoculated intrabronchially with SVV. (A)
Varicella rash on skin of monkey 24953 9 days after intrabronchial infection. (B) Detection of SVV DNA by real-time PCR in punch biopsies of skin from all
4 monkeys during varicella. (C) Immunohistochemical detection of SVV antigen with antibodies directed against SVV glycoproteins H and L in skin of
monkey 24953 during varicella, with staining in superficial and deep layers of skin. (D) Skin staining of monkey 24953 with normal rabbit serum. (E) SVV
DNA levels in peripheral blood mononuclear cells (PBMC) and samples of all monkeys as assessed by quantitative real-time PCR. SVV DNA was first
detected 7 days post-infection (dpi), peaked at 10 dpi and was not detected 21 dpi. (F) SVV DNA levels in bronchial alveolar lavage (BAL) samples in all
four monkeys as assessed by quantitative real-time PCR. SVV was first detected in BAL as early as 3 dpi, peaked 3–7 dpi and was not detected 17 dpi.
doi:10.1371/journal.ppat.1000657.g001
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response
Resolution of VZV infection in humans correlates with the
development of humoral and cellular immune responses to virus
[31]. A hallmark of the antiviral immune response is expansion of
antigen-specific T and B cells, which can be measured by flow
cytometry [32] based on expression of Ki67, a nuclear protein
involved in DNA replication. To determine whether SVV
infection in rhesus monkeys elicits similar immune responses as
VZV, we measured the magnitude and kinetics of the B and T cell
responses after the appearance of rash.
To assess the B cell response, we measured the fold increase in the
number of Ki67+ isotype-switched B cells. PBMCs and BAL cells
were stained with antibodies directed against CD20, IgD and CD27
to distinguish between three subsets: CD27-IgD+ (most likely naı ¨ve),
CD27+IgD+,a n dC D 2 7 +IgD2 (isotype-switched B cells) [33]
(Figure 3A, left). Cells were then fixed and the nuclear membrane
waspermeabilizedbeforestainingwithanti-Ki67antibody(Figure3A,
middle and right). SVV infection induced a robust proliferation of
CD27+IgD+ as well as isotype-switched CD27+IgD2 B cells in
PBMCs as indicated by an increase in the frequency of Ki67+ cells on
dpi 14 compared to dpi 0 (Figure 3A middle and right panels;
Figure 3B and C, respectively). Analysis of BAL samples revealed
an increased frequency of proliferating CD27+IgD2 B cells, that
were detected earlier (7 dpi) than in PBMCs (14 dpi) (Figure 3D). No
significant proliferation of CD27+IgD+ B cells was found (data not
shown). The SVV-specific IgG titer revealed an IgG response by 12
dpi that peaked18–21 dpi (Figure 3E).
Rhesus macaques inoculated with SVV generate a T cell
response
T cell proliferation in PBMCs (Figure 4) and BAL (Figure 5) was
also determined by measuring the relative (fold) increase in the
number (PBMC) or percentage (BAL) of Ki67
+. At each time point,
PBMCs and BAL cells were stained with antibodies directed against
CD4, CD8, CD28 and CD95 (Figure 4A and 5A, left) to delineate
naı ¨ve (CD28+CD952), central memory (CD28+CD95+, CM) and
effector memory (CD282CD95+, EM) T cell subsets [34]. Cells
were fixed, permeabilized and incubated with anti-Ki67 antibodies
(Figures 4A and 5A, middle and right). Previous studies showed that
naı ¨ve T cells identified using these markers were CCR7+.E M
T cell were CCR7-, whereas CM T cells contained a transitional
population that lacked CCR7 expression [32,35]. Both naı ¨ve and
memory T cells were detected in PBMCs (Figure 4A, left), whereas,
as expected, only memory T cells were present in BAL cells
(Figure 5A, left). SVV infection induced robust T cell proliferation
as shown by an increase in Ki67+ CD8 EM T cells (Figures 4A and
5A, middle and right).
SVV infection resulted in proliferation of both CM and EM T
cell subsets in PBMCs that peaked at 14 dpi in all 4 monkeys
(Figure 4A, right; Figure 4B–E). In BAL cells, CD4 EM T cell
proliferation was detected at 7 dpi in all animals (Figure 5C).
Table 1. Primers and probes specific for the SVV ORFs used in
real-time PCR.
ORF
a Direction Sequence (59–39)5 9-location
b
21 Forward GACACATCAGCGGTTTGCA 32406
Reverse TGCACGCTGTGTTAGAATTCG 32541
Probe TCCATCCTGAACGATAGGCATGTCATAAAGA 32517
29 Forward CGTCTTATAGGGCTGGCAAGC 54451
Reverse CTAACGCGCCATGAAGCAT 54520
Probe CGTATCAACGGCAAAATAAACGCGTGG 54473
40 Forward GGATGCGTTATTGACGCTTCA 74906
Reverse TCCAGCATCCGGAGCTATTG 74993
Probe CGGATATGGCAGAACGTACCACTCCAA 74938
61 Forward ACACAGCGCTAATGAGAAGCC 104077
Reverse GAAAGACGCTGCTGTTGTCG 104012
Probe CAACCCCGCGTGTTGGCCC 104051
62 Forward CGATGAGCAGGCGGTATGA 107326
Reverse GGTAGGCCATGGTGGCATAA 107246
Probe CGCCCAAAAACATTTCATACTGCAAAGTTTAA 107306
63 Forward CGTACGCTCCGCTGACAAA 111144
Reverse TGCTGTCCAATGCGTTTCTG 111206
Probe CGTCCCCGCACAATTACAGCGC 111164
66 Forward TTGCTACTAACGCACCGGAA 113637
Reverse CCTGCGCTCCAAATATCGAC 113706
Probe CAAGGGATCCATACGGCCCGG 113664
aNumbers designate the SVV ORFs.
bNumbers designate the location of the 59-end of the primers on the SVV
genome (Genbank accession number AF275348).
doi:10.1371/journal.ppat.1000657.t001
Table 2. SVV DNA content in ganglionic and non-ganglionic
tissues from rhesus macaques inoculated intrabronchially
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bPooled ganglia from the lumbar and the sacral regions.
cnd = not done.
doi:10.1371/journal.ppat.1000657.t002
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at 7 dpi in monkeys 24953 and 25043 and 14 dpi in monkeys
23986 and 23942 (Figure 5B, D and E). Interestingly, varicella
rash was detected slightly earlier in monkeys 24953 and 25043
(day 7) compared to monkeys 23986 and 23942 (day 10), which
could explain the earlier proliferative response observed in
monkeys 24953 and 25043. Furthermore, 25043 had the lowest
viral load, least amount of rash and lowest T cell proliferation,
which suggests that T cell proliferation correlates with viral load.
Overall, as described for B cells, T cell proliferation occurred
earlier in BAL compared to peripheral blood.
To determine the frequency of SVV-specific T cells, we used
intracellular cytokine staining analysis to detect IFNc/TNFa-
producing T cells after stimulation with SVV antigen. Since SVV
is highly cell-associated and cell-free SVV is difficult to obtain, we
used an SVV lysate (1 mg/well) to stimulate PBMCs and BAL cells
isolated from infected monkeys at different dpi in the presence of
Brefeldin A, which blocks protein export. This allowed efficient
detection of cytokine-producing CD4 cells, which responded to
SVV but not to the vaccinia (VV) lysate (Figure 6A); CD8 T cells
showed no detectable response to either lysate (Figure 6A, right),
likely due to the absence of free virus in the SVV lysate; another
possibility is a low efficacy of cross-presentation of MHC class I-
associated viral antigens due to the low abundance of viral proteins
compared to cellular proteins in the lysate. Previous studies with
VZV viral lysates did not detect CD8 T cell responses ex vivo
without prior stimulation [36]. SVV-specific CD4 T cells were
detected at 7 dpi, with a peak at 14 dpi in both BAL (Figure 6B
and C) and PBMCs (Figure 6D and E), but the frequency of
responding CD4 CM and EM T cells was higher in BAL
compared to PBMCs. After 14 dpi, the frequency of responding
CD4 T cells decreased and a stable memory population was
established.
Since VZV infection is associated with the development of
cytolyticCD4andCD8T cells[37,38,39],we measuredanincrease
in granzyme B, a major component of cytolytic granules and an
indicator of cytolytic activity. A considerable increase in granzyme
B+ EM CD8 and CD4 T cells in both BAL (Figure 7B and C) and
PBMCs (Figure 7D and E) was found in all samples as compared to
levels at 0 dpi (Figure 7A, middle). These data indicate that SVV
infection elicits a T cell response with cytotoxic potential.
Discussion
In this study, we show for the first time that intrabronchial
infection of rhesus macaques with SVV results in viremia and
varicella rash followed by resolution of viremia and establishment of
SVV latency in ganglionic neurons. The incubation period for SVV
(7–10 days) seems to be slightly shorter than that of VZV, which has
been estimated at 14 days. As early as 2 months after varicella, SVV
DNA was found exclusively in ganglia and not in any of multiple
visceral tissues examined. Transcripts corresponding to SVV ORFs
21, 61, 62, 63 and 66, but not 40 or 29, were also found in latently
infected ganglia (Table 3). Except for ORF 61, the SVV transcripts
found in ganglia are the same as those detected in latently infected
human ganglia [27]. The detection of SVV ORF 61 RNA in
latently infected monkey ganglia suggests that it should be searched
for in human ganglia latently infected with VZV. Finally, like VZV,
SVV ORF 63 protein was seen exclusively in the cytoplasm of
neurons in latently infected monkey ganglia.
Two different NHP models of SVV infection have been
developed. African green or Cynomolgus monkeys inoculated
intratracheally with SVV develop viremia followed by varicella
and an antibody response [23,40,41]. Unfortunately, this model
does not results in latency but rather the persistence of SVV DNA
in blood, lung and liver for months to years after experimental
infection [24,25]. More recently, Mahalingam et al., developed a
natural infection model whereby naı ¨ve African green or
Cynomolgus monkeys were exposed to experimentally inoculated
cage mates [21,26]. Although naturally infected animals developed
varicella followed by the establishment of latency, viremia and
seroconversion were not consistently observed [21,26]. Thus, in
our initial experiments we inoculated two rhesus macaques
intravenously. The first monkey developed persistent viremia.
The second monkey was re-challenged with SVV 4 months later,
Table 3. Abundance of SVV-specific transcripts in SVV DNA-
positive ganglia (per 1–3 mg RNA) assessed by qRT-PCR.
Monkey
number Tissue SVV ORFs
21 29 40 61 62 63 66
23942 Trigeminal 0002 1 70 0 0
Thoracic 0005 2 0 2 0
Lum/sac 0003 8 9trace 0 0
23986 Trigeminal 3008 0 70 7 0
Cervical 4002 5 0 0 0 9 0
Thoracic 0002 7 0 0 5 6 0
Lum/sac 0005 3 0 0 3 1 80
24953 Trigeminal 0005 1 0 0 0
Cervical 0005 5 0 0 0
Thoracic 0006 0 06 6 3
Lum/sac 0008 0 0 0
25043 Trigeminal 0001 0 0 0 0
Cervical 0006 0 0 0
Thoracic 0002 1 0 0 0
Lum/sac 0000 0 0 0
doi:10.1371/journal.ppat.1000657.t003
Table 4. Abundance of SVV ORF 61 sense and antisense
transcripts (per 1–3 mg RNA) in SVV DNA-positive ganglia
assessed by qRT-PCR.
Monkey




23942 Trigeminal 25 153
Thoracic 14 62
Lum/Sac 80 584
23986 Trigeminal 527 7300
Cervical 1277 8609
Thoracic 1135 9835
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was detected only on 4 dpi, indicative of subclinical infection.
These data suggested that the immune response generated after
primary infection protects against subsequent exposures. Encour-
aged by the results in the latter monkey and the fact that varicella
virus is naturally transmitted through inhaled aerosolized viral
droplets, we redesigned our strategies to deliver virus by the
intrabronchial route. This strategy led to viremia, varicella, the
establishment of latency in sensory ganglia, and the development
of SVV-specific cellular and humoral immune responses. Although
the difference in the route of infection (intratracheal versus
intrabronchial) cannot be discounted, it is very likely that the
change in nonhuman primate species is the main reason for
resolution of viremia. For example, African green monkeys
infected with simian immunodeficiency virus (SIV) show high
levels of viremia without signs of simian AIDS. In contrast, rhesus
macaques infected with SIV develop a profound loss of CD4 T
cells and simian AIDS [42,43].
As described for VZV [44,45,46], SVV infection resulted in
viremia and in the detection of SVV DNA in T cells (CD4, CD8
and cd), B cells, macrophages and dendritic cells (data not shown).
The increased levels of SVV DNA in BAL cells compared to
PBMCs are consistent with the severity of VZV infection seen in
lungs of humans with varicella [47,48,49,50]. The presence of
SVV ORF61 transcripts was the only difference between VZV
and SVV latency. SVV ORF 61 protein shares 37% amino acid
identity with that of VZV ORF 61 protein with highly conserved
domains [51]. Transcripts associated with VZV ORF61 have not
been reported in latently infected human ganglia. Nevertheless,
given parallels between varicella latency in humans and monkeys,
a more aggressive search for VZV ORF 61 transcripts in humans
is indicated. Interestingly SVV ORF 61 protein was detected only
sparingly despite the presence of a high level of transcripts. It is
unlikely that the low level detection of SVV ORF61 is due to poor
sensitivity of the antibody used. Rather, the high number of
antisense transcripts detected in same ganglia could be inhibiting
protein translation.
The kinetics of the immune response to SVV in rhesus
macaques also parallel findings in humans infected with VZV.
In humans, antibodies are detected at about 6 days after the onset
of varicella rash, and we found peak SVV-specific IgG titers about
Table 5. Detection of SVV antigens in latently infected rhesus
macaque ganglia.
Monkey number Tissue SVV antigens (ORFs)
61 63
23942 Trigeminal 2 +
Lum/sac 2 +
23986 Trigeminal 2 +
Thoracic 2 +









and = not done.
doi:10.1371/journal.ppat.1000657.t005
Figure 2. Detection of SVV ORF 63 protein in the cytoplasm of neurons in monkey ganglia latently infected with SVV.
Paraformaldehyde-fixed, paraffin-embedded sections (5 m) of thoracic (th) ganglia from monkey 23986, trigeminal (tg) ganglia from monkey 23942
and thoracic ganglia from monkey 24953 were analyzed by immunohistochemistry using a 1:800 dilution of rabbit anti-VZV ORF 63 (anti-VZV63), a
1:1000 dilution of rabbit anti-VZV ORF 61 (anti VZV61) antiserum or normal rabbit serum (NRS). SVV ORF 63 protein was detected in thoracic and
trigeminal ganglia of monkeys 23986 and 23942, respectively, and SVV ORF 61 protein was detected in thoracic ganglia of monkey 24953. No SVV
antigen was seen using normal rabbit serum. SVV ORF63 protein, but not SVV ORF61 protein was detected in trigeminal ganglia of monkey 23942.
doi:10.1371/journal.ppat.1000657.g002
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PLoS Pathogens | www.plospathogens.org 6 November 2009 | Volume 5 | Issue 11 | e1000657Figure 3. SVV infection of rhesus macaques elicits a B cell response after the appearance of varicella rash. B cells were separated into
three subsets based on expression of IgD and CD27: CD272IgD+; CD27+IgD+; and isotype-switched CD27+IgD2 cells. A representative profile from
PBMCs obtained from monkey 24953 on day 0 (A, left) is shown. B cell proliferation within CD27+IgD+ and CD27+IgD2 subsets was measured using
flow cytometry based on expression of the nuclear protein Ki67, which is up-regulated upon entry into the cell cycle. B cell proliferation was minimal
before SVV infection (0 dpi, A, middle), but increased dramatically 14 dpi (A, right). Throughout the course of SVV infection in all 4 monkeys, the
number of Ki67+ CD27+IgD+ (panel B) and CD27+IgD2 B cells (C) increased dramatically 14 dpi compared to 0 dpi in PBMCs. In BAL of all 4 monkeys,
increased numbers of Ki67+ IgD2CD27+ B cells were seen throughout the course of infection compared to 0 dpi (panel D), although no significant
proliferation of IgD+CD27+ B cells was detected (data not shown). In all 4 monkeys, SVV-specific IgG antibodies appeared 7 dpi, peaked 18–21 dpi (as
detected by ELISA) and remained stable up to 70 dpi (E).
doi:10.1371/journal.ppat.1000657.g003
Primate Model for Varicella Zoster Virus Infection
PLoS Pathogens | www.plospathogens.org 7 November 2009 | Volume 5 | Issue 11 | e1000657Figure 4. SVV infection of rhesus macaques elicits a robust peripheral T cell response. CD4 and CD8 T cells were separated into three
subsets based on expression of CD28 and CD95: naı ¨ve (CD28+CD952); central memory (CM, CD28+CD95+); and effector memory (EM, CD282CD95+)
cells. A representative profile of CD8 T cell subsets of monkey 24953 on 0 dpi is shown (A, left). T cell proliferation was measured as described in
Figure 3 based on expression of the nuclear protein Ki67 using flow cytometry. T cell proliferation dramatically increased 14 dpi (A, right) compared
to 0 dpi (A, middle). Fold increases (relative to 0 dpi) in the numbers of Ki67+ CD4 CM and EM (B and C) and CD8 CM and EM T cells (D and E) in
PBMCs indicate a peak proliferative response of all T cell subsets 14 dpi in all monkeys (B–E).
doi:10.1371/journal.ppat.1000657.g004
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PLoS Pathogens | www.plospathogens.org 8 November 2009 | Volume 5 | Issue 11 | e10006578 days after rash (18 dpi). VZV-specific T cells are present at 3
days after the onset of varicella in humans [52]. We detected T cell
proliferation after SVV infection at 7 dpi, with a peak at 14 dpi,
i.e., at about 4 days post-rash, and SVV-specific IFNc-secreting T
cells were also first detected at 7 dpi and peaked at 14 dpi. We also
detected an increase in granzyme B+ T cells indicative of a
Figure 5. SVV-induced T cell proliferation occurs earlier in BAL than in peripheral blood. In contrast to PBMCs, BAL revealed only CM and
EM T cells subsets as illustrated by a profile of CD8 T cells from 24953 day 0 (A, left). T cell proliferation was measured as described in Figure 3. A
representative example of Ki67 staining within CD8 EM T cells from monkey 24953 on 0 dpi (A, middle) and 14 dpi (A, right) is shown. Fold increases
(relative to 0 dpi) in the percentages of Ki67+ CD4/CM, CD4/EM, CD8/CM and CD8/EM T cells subsets in BAL from all 4 monkeys indicate a robust
proliferative response of all T cell subsets 7–14 dpi in all monkeys (B–E).
doi:10.1371/journal.ppat.1000657.g005
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PLoS Pathogens | www.plospathogens.org 9 November 2009 | Volume 5 | Issue 11 | e1000657Figure 6. Appearance of SVV-specific CD4 T cells correlates with Ki67 expression. The frequency of SVV-specific T cells in PBMCs and BAL
was measured by intracellular cytokine staining. (A) Representative examples of IFNc and TNFa production by CD4 CM, CD4 EM, CD8 CM and CD8 EM
T cells from BAL of monkey 24953 7 dpi after stimulation with vaccinia virus (VV) lysate (negative control) and SVV lysate. A robust response by CD4
CM and CD4 EM cells was detected after exposure to SVV lysates, but not VV lysates (A, left), whereas no response by CD8 CM and CD8 EM cells was
seen after exposure to either SVV or VV lysate (A, right). The percentage of responding (IFNc+ alone or both IFNc+ and TNFa+) CD4 CM and CD4 EM T
cells in BAL (B and C) and PBMCs (D and E) in all 4 monkeys was determined and averaged. At all time points, more SVV-responsive CD4/CM and CD4/
EM cells were found in BAL (B and C) than in PBMCs (D and E).
doi:10.1371/journal.ppat.1000657.g006
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PLoS Pathogens | www.plospathogens.org 10 November 2009 | Volume 5 | Issue 11 | e1000657cytotoxic T cell response as described for VZV [53]. In peripheral
blood, the peak of the proliferative burst occurred 14 dpi with
23986 displaying the highest level of proliferation in all T cell
subsets analyzed. Interestingly, 23986 displayed the most extensive
rash and the highest viral load in ganglia. On the other hand,
monkey 25043, which had the least amount of rash, viral DNA
Figure 7. Increased granzyme B expression in EM T cells after SVV infection. (A) Intracellular granzyme B expression in CD4 and CD8 T cell
subsets as assessed by flow cytometry. An example of CD8 T cell subsets in BAL on day 0 from animal 24953 is shown in left panel. Frequency of
granzyme B+ EM T cells increased dramatically after SVV infection as shown in BAL-resident CD8 EM T cells from monkey 24953 (A, middle and right),
while the increase in granzyme B+ CM T cells was comparatively modest (data not shown). Measurement of fold increases (compared to 0 dpi) in the
percentages of granzyme B-expressing CD8/EM and CD4/EM from BAL and PBMCs during the course of infection indicated a significant increase in
these percentages in both BAL and PBMCs 12–14 dpi in all samples (B–E).
doi:10.1371/journal.ppat.1000657.g007
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had a low proliferative T cell response. The kinetics of T cell
proliferation in BAL correlated with the onset of the rash, with T
cells form 24953/25043, which showed signs of varicella on day 7,
proliferating earlier (7 dpi) that T cells from 23942/23986, which
showed sings of varicella on day 10. These data suggest a
correlation between the extent of rash, the development of the T
cell response and the extent of viral load and expression in latently
infected ganglia. Overall, SVV-infected rhesus macaques develop
an adaptive immune response to virus with kinetics like those seen
in humans after primary infection with VZV.
Together, our data indicate that SVV infection of rhesus
macaques provides a robust animal model that recapitulates
clinical, virological and immunological hallmarks of VZV infection
in humans. This model will provide unique opportunities to define
hostand viralfactorsneededtomaintainlatencyandtocharacterize
immune correlates needed for protection against VZV infection.
Future studies will dissect the antiviral functions of the antibody
response (neutralization, complement fixation, ADCC). It will also
be important to characterize the specificity and function of SVV-
specific CD4 and CD8 T cells, and to determine if the SVV
homologues of VZV ORFs 4, 10, 29, 62, 63, gI and gE are also
immunogenic in rhesus macaques [39,54,55,56,57].
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the Oregon
National Primate Research Center Institutional Animal Care and
Use Committee (IACUC#0779).
Cells and virus
The Delta strain of SVV was propagated in Vero cells as
described [17]. SVV cell lysate were obtained by scraping SVV-
infected Vero cells at the height of a cytopathic effect (CPE).
Infected cells were pelleted by centrifugation at 500G for 5 min
and resuspended in RPMI medium and sonicated using 7 pulses of
70–80 W (Sonicator 3000, Misonix) followed by centrifugation at
100G for 5 min. Vaccinia virus (VV) WR strain lysates were
obtained from Vero cells infected at a multiplicity of infection of
0.1, harvested by scraping at the height of CPE, and treated as
described for SVV-infected cells. Total protein concentration was
determined by standard Bradford assay (Bio-Rad, Hercules, CA).
1 ug/well was used in T cell stimulation assays.
Monkeys
Four 3-to-4-year-old male rhesus macaques (Macaca mulatta),
seronegative for SVV and without any history of chronic illness,
were inoculated intrabronchially with 4610
5 PFU SVV. Rhesus
macaques were sedated by ketamine (10 mg/Kg) and positioned
in dorsal recumbency and monitored continuously with a pulse
oximeter. A pediatric fiber optic endoscope was introduced into
the tracheal lumen with the aid of a laryngeal scope followed by
instillation of 1 ml of 1% lidocaine to control bronchospasm. The
tip of the bronchoscope was gently wedged into a right subsidiary
bronchus, and the virus inoculum was infused in a volume of 2 ml
followed by additional infusion of a 5 ml aliquot of sterile,
pyrogen-free saline into the bronchus. Heparinized blood and
bronchial alveolar lavages (BAL) were obtained after ketamine
(10 mg/kg body weight) sedation. PBMCs were isolated using a
histopaque gradient (Sigma) as per the manufacturer’s recom-
mendation. The absolute number of lymphocytes/ml blood was
obtained using a complete blood count machine (Hemavet, Drew
Scientific). BAL samples were pelleted and resuspended in RPMI
medium supplemented with 10% FBS, penicillin/streptomycin
and L-glutamine. During varicella, monkeys were anesthetized
and a punch biopsy of the area of rash was obtained and divided
into two portions; one portion was used to extract total DNA, and
the second portion was fixed in 4% paraformaldehyde and
paraffin-embedded. Monkeys were euthanized at 73 or 105 dpi
and ganglionic and non-ganglionic tissues were harvested at
necropsy. Tissues were divided into two portions; one portion was
snap-frozen for DNA extraction and the other portion was fixed in
4% paraformaldehyde and paraffin-embedded. Ganglia from the
two sides of the neuraxis were kept separate. Pooled ganglia from
specific dermatomes and from one side of the neuraxis were snap-
frozen in liquid nitrogen, and pooled ganglia from the same
dermatomes of the other side were fixed in 4% paraformaldehyde
and paraffin-embedded.
DNA/RNA extraction and real-time PCR
DNA was extracted from heparinized whole blood, from skin
biopsies and from BAL as well as from portions of frozen lung and
ganglia using the Qiagen genomic DNA extraction kit (Qiagen) as
described [58]. RNA was extracted from SVV DNA-positive
ganglia as previously described [59]. SVV DNA loads were
determined by real-time PCR using primers and probes specific
for ORF 21 using the ABI 7700 and ABI StepOne instruments
(Applied Biosystems).
Oligonucleotide primers (Integrated DNA Technologies) and
probes specific for SVV ORFs 21, 29, 40, 61, 62, 63 and 66 were
used to amplify and detect SVV DNA and RNA in monkey tissues.
Table 1 lists the primer sequences and probes used. Total RNA
(1 mg) was treated with 1 U of DNase (Invitrogen) for 15 min at
room temperature in a 10-ml volume The reaction was terminated
by the addition of 1 ml 25 mM EDTA and heating at 65uC for
10 min and transferred to ice. Reverse transcription was performed
using the Transcriptor First Strand cDNA Synthesis Kit (Roche)
with anchored-oligo(dT)18 primers and random hexamer primers,
as per manufacturer’s instructions in a total volume of 20 ml. The
reaction was then diluted to 50 ml with nuclease-free water.
Real-time PCR was performed in a 20-ml volume of 1X qPCR
Mastermix (Abgene Products) containing 900 nM concentrations
of each SVV ORF specific primer, 250 nM probe and 10% of
each cDNA sample using the 7500-Fast real-time PCR system
(Applied Biosystems). All samples were analyzed in triplicate.
Amplification conditions included initial denaturation at 95uC for
15 min followed by 50 two-step cycles of 15 sec at 95uC and 1 min
at 60uC. Sense and anti-sense transcripts specific for SVV ORF61
were analyzed using SVV ORF 61 reverse or forward primer
(Table 1), respectively in the reverse transcription step.
Measurement of T and B cell proliferation
PBMC and BAL cells were first stained with surface antibodies
directed against CD8b (Beckman Coulter), CD4, CD28 and
CD95 (Biolegend) to delineate naive, central and effector memory
T cell subsets as described [32,34,60]. Cells were then fixed and
permeabilized as per the manufacturer’s recommendation using
fixation buffer (Pharmingen). The nuclear membrane was
subsequently permeabilized using fixation buffer supplemented
with 10% DMSO, and cells were stained with an antibody
directed against Ki67 as per the manufacturer’s recommendation
(Pharmingen). Samples were prepared using the LSRII instrument
(Beckton Dickenson) and FlowJo software (TreeStar). The
percentages of Ki67+ cells within T and B cell subsets were
converted to absolute numbers using the lymphocyte numbers/ml
Primate Model for Varicella Zoster Virus Infection
PLoS Pathogens | www.plospathogens.org 12 November 2009 | Volume 5 | Issue 11 | e1000657whole blood obtained using a complete blood count machine
(Hemavet). For instance, the number of Ki67
+ CD8 EM T cells in
PBMCs was calculated as: number of lymphocytes x percentage of
CD8 T cells x percentage of EM CD8 T cells x percentage of
Ki67
+ cells within CD8 EM.
Intracellular cytokine staining
PBMCs and BAL cells were stimulated with lysates from SVV
(1 mg) or VV (negative control) or with CD3 (0.1 mg/sample,
positive control) for 12 h followed by incubation with Brefeldin A
(Sigma) for 6 h to block cytokine export. After stimulation, cells
were stained with surface antibodies directed against CD4, CD8b,
CD28 or CD95 as described for Ki67 staining above. Samples
were then fixed and permeabilized using fixation buffer (Pharmin-
gen) before addition of antibodies to detect IFNc and TNFa
(Biolegend). Samples were prepared on the LSRII and analyzed by
FlowJo software as described above.
Granzyme B staining
PBMCs and BAL were stained with surface antibodies directed
against CD8b, CD4, CD28 and CD95 to delineate naive, central
and effector memory T cell subsets as described above. Cells were
then fixed and permeabilized using fixation buffer (Pharmingen)
before the addition of anti-granzyme B antibody (Pharmingen).
The number of granzyme B+ cells was calculated as: number of
lymphocytes obtained using the complete blood count machine x
percentage CD8 T cells x percentage EM cells x percentage
granzyme B+ cells.
SVV-specific enzyme-linked immunoabsorbent assay
(ELISA)
ELISA plates were coated with SVV lysates (0.25 ug/ml)
overnight at 4uC, washed 3 times with 0.05% Tween-PBS and
incubated with 3-fold dilutions of plasma in triplicate for 1 h. After
3 additional washes with 0.05% Tween-PBS, plates were
incubated with horseradish peroxidase (HRP)-conjugated anti-
rhesus IgG (Nordic Immunology) for 1 h, followed by addition of
chromogen OPD substrate to allow detection and quantitation of
bound antibody molecules. End-point IgG titers were calculated
using log-log transformation of the linear portion of the curve, and
0.1 OD units as cut-off. For each plate, a positive control sample
(pooled plasma obtained from monkeys 23974 and 23986 at
necropsy) was used to normalize ELISA titers among assays, and a
negative control sample (pooled plasma from specific-pathogen-
free rhesus macaques) was used to ensure specificity of the assay
conditions.
Immunohistochemistry
Sections (5 mm) of paraformaldehyde-fixed, paraffin-embedded
skin, lung or ganglia were analyzed for SVV antigen expression by
immunohistochemistry [21,29] using: a 1:800 dilution of normal
rabbit serum; a 1:2000 dilution of a mixture of polyclonal anti-
peptide antibodies raised in rabbits against SVV gH and gL [61]; a
1:1000 dilution of polyclonal anti-VZV ORF 61 protein [62]; or a
1:800 dilution of anti-VZV ORF 63 protein [29]. All reagents
were diluted in PBS containing 5% normal sheep serum and
adsorbed using acetone-fixed uninfected Vero cells and acetone-
fixed normal human liver powder. Sections from skin punch
biopsies were stained using a 1:500 dilution of normal rabbit
serum or rabbit polyclonal antibodies against gH/gL diluted in
PBS containing 5% normal sheep serum.
Supporting Information
Figure S1 VZV ORF 63- and 61-specific antibodies cross-react
with SVV ORF63 and 61 proteins in virus-infected cells. SVV-
infected (A, C) and uninfected (B, D) Vero cells in culture were
analyzed by immunohistochemistry using a 1:800 dilution of
rabbit anti-VZV ORF 63 (A, B) or a 1:1000 dilution of rabbit anti-
VZV ORF 61 antiserum (C, D). ORF 61 and 63 proteins were
detected only in infected cells.
Found at: doi:10.1371/journal.ppat.1000657.s001 (3.49 MB TIF)
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